D-0357-2026 Class II Ongoing

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

FDA drug recall D-0357-2026 was initiated by Teva Pharmaceuticals USA, Inc on Jan 29, 2026 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is ongoing. Affected quantity: 19,056 bottles.

Recall Details

Product Type
Drugs
Report Date
Mar 11, 2026
Initiation Date
Jan 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
19,056 bottles

Product Description

Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11

Reason for Recall

Failed Dissolution Specifications

Distribution Pattern

Nationwide

Code Information

Lot#: a) 0686H251, 0687H251, 10688H251, Exp.: 02/2027. .

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0357-2026
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0357-2026. Report a data issue: hello@regdatalab.com.